Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases.

JAMA neurology·2026

Same author

Editorial: Autoimmune diseases of the central nervous system.

Seminars in immunology·2026

Same author

Therapeutic immune tolerance for central nervous system autoimmune diseases - Prospects, challenges and pitfalls.

Seminars in immunology·2026

Same author

Inflammatory transcriptomic signatures in a human cellular NMOSD model reveal upregulation of NF-κB and IL6 pathways.

Scientific reports·2025

Same author

Preanalytical stability of plasma calcitonin gene-related peptide: clinical and research implications.

The journal of headache and pain·2025

Same author

Treatment response in children with relapsing MOG-antibody associated disease.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2025

Same journal

Computational Study of ADME-TOx from Selected Phytocompounds of Solanum tuberosum and Cucumis sativus.

Current medicinal chemistry·2026

Same journal

QSAR-Based Strategies for Selective-HDAC6 Inhibitor Development: A Detailed Review.

Current medicinal chemistry·2026

Same journal

Breaking New Ground in Oncology: FDA Acceptance of Vepdegestrant NDA Marks a Milestone for PROTAC Therapies in Breast Cancer.

Current medicinal chemistry·2026

Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026

Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026

Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Biological markers for multiple sclerosis.

Andreas Lutterotti¹, Thomas Berger, Markus Reindl

¹Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

Current Medicinal Chemistry

|August 21, 2007

Summary

This summary is machine-generated.

This review explores biomarkers in cerebrospinal fluid and blood for multiple sclerosis (MS). These markers, including antibodies and immune cells, aid in diagnosing MS, predicting its course, and guiding treatment responses.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: Jun 27, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

Neurology
Immunology
Biomarker Research

Background:

Multiple sclerosis (MS) is a primary cause of neurological disability in young adults.
MS pathogenesis involves autoimmune responses targeting myelin sheath autoantigens.
MS exhibits significant heterogeneity in clinical, histopathological, and immunological aspects.

Purpose of the Study:

To review current research on identifying biomarkers for MS in cerebrospinal fluid and blood.
To focus on antibodies, immune cells, and soluble molecules as potential MS biomarkers.
To evaluate biomarkers for MS diagnosis, clinical course prediction, disease activity monitoring, and treatment response assessment.

Main Methods:

Review of existing scientific literature on MS biomarkers.
Analysis of antibodies targeting myelin and non-myelin antigens.
Examination of immune system cells and soluble molecules in the brain and bodily fluids.

Main Results:

Biomarkers in cerebrospinal fluid and blood show promise for MS diagnosis.
Specific markers can help predict disease progression and clinical outcomes.
Immune-related markers are crucial for assessing disease activity and treatment efficacy.

Conclusions:

Biomarker identification is essential for personalized medicine in MS.
A combination of markers may offer a comprehensive approach to MS management.
Further research is needed to validate and implement these biomarkers in clinical practice.